Vistin Pharma ASA
Research Vistin Pharma ASA (VISTN) on Bullrun: valuation model: 37.5% undervalued, market cap NOK 913.50M, P/E 12.3, dividend yield 7.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVISTN
- ExchangeOL
- CountryNorway
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyNOK
- Valuation signal37.5% undervalued
- Market capNOK 913.50M
- P/E12.3
- Dividend yield7.2%
- Financial periodQ1 2026
- RevenueNOK 112.21M
- Net incomeNOK 21.49M
- Free cash flow-NOK 9.58M
- Gross margin64.9%
Valuation Snapshot
Bullrun's latest valuation model marks Vistin Pharma ASA as 37.5% undervalued; latest market cap is NOK 913.50M; P/E is 12.3; dividend yield is 7.2%.
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.
Frequently asked questions
Is Vistin Pharma ASA overvalued or undervalued?
Bullrun's valuation model currently marks Vistin Pharma ASA as 37.5% undervalued.
What is Vistin Pharma ASA's market cap?
Vistin Pharma ASA's market capitalization is NOK 913.50M.
What is Vistin Pharma ASA's P/E ratio?
Vistin Pharma ASA's price-to-earnings (P/E) ratio is 12.3.
Does Vistin Pharma ASA pay a dividend?
Vistin Pharma ASA has a dividend yield of 7.2%.
What does Vistin Pharma ASA do?
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible;